Horizon Discovery adds lucrative new revenue stream
Cambridge based gene editing world leader Horizon Discovery has created a potentially lucrative new revenue stream with an astute piece of transatlantic business.
The UK trailblazer has signed a non-exclusive out-licensing agreement with a US-based immuno-oncology therapeutics developer for Horizon’s proprietary technologies to support the development and manufacture of a novel biomanufacturing cell line for commercial use.
Horizon has licensed to the US partner a novel cell line engineering technology as well as non-exclusive rights to Horizon’s proprietary Helitron transposon gene editing technology.
While financial details are not being disclosed, Horizon CEO Dr Darrin Disley (pictured above) said he expects the fruits of the deal to provide a significant additional revenue stream for the group going forward.
The intermediate cell line will enable rapid development of a wide range of cell lines designed to produce specific antibodies – enabling more cost effective and efficient antibody manufacture in the future for all the Partner’s development programmes.
Horizon retains commercial rights to the improved cell line and Helitron transposon technology at the heart of the initiative. It will seek additional third-party licence deals for these technologies and others under development to enable cutting edge science and to drive novel workflows that are at the core of our partners’ businesses.
Dr Disley said: “Innovation and leverage of our capabilities, of which both intermediate cell line engineering and transposon technologies are key examples, are important parts of our strategy as we continue to develop novel ways to address the key challenges facing our customers.
“This agreement demonstrates the impact of this approach and the value of licences to our novel technologies and we anticipate this becoming a significant additional revenue stream for the group going forward.”